Free Cash Flow

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

Beyond the press release: Why Terreno's 107,000 sq. ft. deal with the Secret Service is a major indicator for the industrial real estate market.

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

Osisko Development is betting big on BC's historic Cariboo region, launching a massive drilling program to uncover new gold and expand its flagship project.

Antero Resources executes a complex asset swap, doubling down on the Marcellus Shale. We break down the financial engineering behind the multi-billion dollar deal.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.

Beyond marble floors, the new luxury is a seamless, secure, and AI-driven transaction. We explore how tech is reshaping high-end property deals.

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

As REV Group preps its Q4 report, all eyes are on whether its booming specialty vehicle segment can offset volatility in the recreational vehicle market.

With AI creating a data center power crisis, one company's safer, greener nickel-zinc batteries are attracting major investment. Here's why it matters.

A recent tree care acquisition reveals a deeper strategy: private equity is building scale not just for profit, but to deploy AI and revolutionize work.